$4.38
Insights on Ventyx Biosciences, Inc.
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 130.2%
0.23%
Downside
Day's Volatility :8.1%
Upside
7.89%
57.31%
Downside
52 Weeks Volatility :95.39%
Upside
89.21%
Period | Ventyx Biosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 127.75% | -0.5% | 0.0% |
6 Months | -72.78% | 5.9% | 0.0% |
1 Year | -85.88% | 3.1% | -1.9% |
3 Years | -77.35% | 14.2% | -21.8% |
Market Capitalization | 329.2M |
Book Value | $4.12 |
Earnings Per Share (EPS) | -3.3 |
Wall Street Target Price | 10.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.06% |
Return On Equity TTM | -64.56% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -207.8M |
Diluted Eps TTM | -3.3 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.67 |
EPS Estimate Next Year | -2.59 |
EPS Estimate Current Quarter | -0.9 |
EPS Estimate Next Quarter | -0.87 |
What analysts predicted
Upside of 146.58%
Sell
Neutral
Buy
Ventyx Biosciences, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ventyx Biosciences, Inc. | -40.35% | -72.78% | -85.88% | -77.35% | -77.35% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ventyx Biosciences, Inc. | NA | NA | NA | -2.67 | -0.65 | -0.4 | NA | 4.12 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ventyx Biosciences, Inc. | Buy | $329.2M | -77.35% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
BlackRock Inc
Vanguard Group Inc
Citadel Advisors Llc
Goldman Sachs Group Inc
Capital Research & Mgmt Co - Division 3
Logos Global Management LP
Ventyx Biosciences, Inc.’s price-to-earnings ratio stands at None
Read Morewe are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.
Organization | Ventyx Biosciences, Inc. |
Employees | 79 |
CEO | Dr. Sheila K. Gujrathi M.D. |
Industry | Services |
Jianzhi Education Technology Group Company Ltd.
$4.38
-7.98%
Carrols Restaurant Group Inc
$4.38
-7.98%
Bristow Group Inc
$4.38
-7.98%
America's Car-mart Inc
$4.38
-7.98%
Tilly's Inc
$4.38
-7.98%
Gigacloud Technology Inc
$4.38
-7.98%
Destination Xl Group Inc
$4.38
-7.98%
Barrett Business Services Inc
$4.38
-7.98%
Telesat Corp
$4.38
-7.98%